Gene Editing Stocks To Consider After Bluebird Bio’s Breakthroughs
- Thursday, June 16, 2022, 7:19
- Market
- Add a comment
There was some positive news for the sector last week, after gene editing player Bluebird Bio received the unanimous backing of the U.S. Food and Drug Administration’s Cellular, Tissue, and Gene Therapies advisory committees for two separate therapies targeted at cerebral adrenoleukodystrophy and…
About the Author
admin123 has written 23527 stories on this site.
